Platelet HMGB1 steers intravascular immunity and thrombosis.
| Autor: | Maugeri N; Division of Immunology, Transplantation & Infectious Diseases, Istituti di Ricovero e Cura a Carattere Scientifico San Raffaele Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy. Electronic address: maugeri.norma@hsr.it., Manfredi AA; Division of Immunology, Transplantation & Infectious Diseases, Istituti di Ricovero e Cura a Carattere Scientifico San Raffaele Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Dec; Vol. 22 (12), pp. 3336-3345. Date of Electronic Publication: 2024 Aug 22. |
| DOI: | 10.1016/j.jtha.2024.07.030 |
| Abstrakt: | Platelets navigate the fine balance between homeostasis and injury. They regulate vascular homeostasis and drive repair after injury amidst leukocyte extravasation. Crucially, platelets initiate extracellular traps generation and promote immunothrombosis. In chronic human diseases, platelet action often extends beyond its normative role, sparking sustained reciprocal activation of leukocytes and mural cells, culminating in adverse vascular remodeling. Studies in the last decade have spotlighted a novel key player in platelet activation, the high mobility group box 1 (HMGB1) protein. Despite its initial characterization as a chromatin molecule, anucleated platelets express abundant HMGB1, which has emerged as a linchpin in thromboinflammatory risks and microvascular remodeling. We propose that a comprehensive assessment of platelet HMGB1, spanning quantification of content, membrane localization, and accumulation of HMGB1-expressing vesicles in biological fluids should be integral to dissecting and quantifying platelet activation. This review provides evidence supporting this claim and underscores the significance of platelet HMGB1 as a biomarker in conditions associated with heightened thrombotic risks and systemic microvascular involvement, spanning cardiovascular, autoimmune, and infectious diseases. Competing Interests: Declaration of competing interests There are no competing interests to disclose. (Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|